Open AccessJournal Article
Establishment and characterization of a human prostatic carcinoma cell line (PC-3).
TLDR
The establishment, characterization, and tumorigenicity of a new epithelial cell line (PC-3) from a human prostatic adenocarcinoma metastatic to bone is reported, which should be useful in investigating the biochemical changes in advanced prostatic cancer cells and in assessing their response to chemotherapeutic agents.Abstract:
The establishment, characterization, and tumorigenicity of a new epithelial cell line (PC-3) from a human prostatic adenocarcinoma metastatic to bone is reported The cultured cells show anchorage-independent growth in both monolayers and in soft agar suspension and produce subcutaneous tumors in nude mice Culture of the transplanted tumor yielded a human cell line with characteristics identical to those used initially to produce the tumor PC-3 has a greatly reduced dependence upon serum for growth when compared to normal prostatic epithelial cells and does not respond to androgens, glucocorticoids, or epidermal or fibroblast gowth factors Karyotypic analysis by quinacrine banding revealed the cells to be completely aneuploid with a modal chromosome number in the hypotriploid range At least 10 distinctive marker chromosomes were identified The overall karyotype as well as the marker chromosomes are distinct from those of the HeLa cell Electron microscopic studies revealed many features common to neoplastic cells of epithelial origin including numerous microvilli, junctional complexes, abnormal nuclei and nucleoli, abnormal mitochondria, annulate lamellae, and lipoidal bodies Overall, the functional and morphologic characteristics of PC-3 are those of a poorly-differentiated adenocarcinoma These cells should be useful in investigating the biochemical changes in advanced prostatic cancer cells and in assessing their response to chemotherapeutic agentsread more
Citations
More filters
Journal ArticleDOI
Oncogenes in prostate cancer. An update.
TL;DR: Current dogma indicates that oncogenes exist in prostate cancer, but these will be identified only by more intensive investigation, and no oncogene has been correlated conclusively with the initiation or progression of prostate cancer.
Journal ArticleDOI
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.
Lawrence D. True,Kent R. Buhler,Janna E. Quinn,Emily C. Williams,Peter S. Nelson,Peter S. Nelson,Nigel Clegg,Jill A. Macoska,Thomas H. Norwood,Alvin Y. Liu,William J. Ellis,Paul H. Lange,Robert L. Vessella +12 more
TL;DR: A human neuroendocrine/small cell prostate cancer xenograft that was developed from a nodal metastasis of a human prostate carcinoma and that has been propagated as serial subcutaneous implants in severe combined immunodeficient mice for >4 years should prove to be useful in the investigation of mechanisms underlying the androgen-insensitive state of progressive prostate carcinomas.
Journal ArticleDOI
Regulation of vascular endothelial growth factor in prostate cancer
Simone de Brot,Atara Ntekim,Ryan Cardenas,Victoria James,Cinzia Allegrucci,David M. Heery,David O. Bates,Niels Ødum,Jenny L. Persson,Nigel P. Mongan +9 more
TL;DR: This review examines the essential role for angiogenesis in PCa metastases, and focuses in particular on the current understanding of the regulation of vascular endothelial growth factor (VEGF) in localized and metastatic PCa.
Journal ArticleDOI
Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX
Domenica Rea,Vitale Del Vecchio,Giuseppe Palma,Antonio Barbieri,Michela Falco,Antonio Luciano,Davide De Biase,Sisto Perdonà,Gaetano Facchini,Claudio Arra +9 more
TL;DR: 3D PDX PCa mouse models show greater fidelity to the disease, in terms of histopathologic features of implanted tumor, gene and miRNA expression, and metastatic pattern, well describing all tumor progression stages; this characteristic encourages the translation of preclinical results.
Journal ArticleDOI
New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145
Helen E. Jones,Carol Mary Dutkowski,Denise Barrow,Maureen Elaine Harper,Alan E. Wakeling,Robert Ian Nicholson +5 more
TL;DR: The effect of an EGF‐R selective tyrosine kinase inhibitor ZM252868 was evaluated on the proliferation of PC‐3 and DU‐145 prostate cancer cell lines, which are purported to utilize an E GF‐R‐mediated autocrine pathway for regulation of cell growth.